Influence of Silencing TRAF6 with shRNA on LPS/TLR4 Signaling in vitro
10.1007/s11596-010-0343-6
- Author:
CHEN FENG
1
;
HE SHENGSONG
;
QIU RONGYUAN
;
PANG RAN
;
XU JUANJUAN
;
DONG JIHUA
Author Information
1. Department of Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430022, China
- Keywords:
tumor necrosis factor receptor-associated factor-6;
RNA interference;
lipopolysaccharide;
Toll-like receptor 4 signaling;
nuclear factor kappa B
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2010;30(3):278-284
- CountryChina
- Language:Chinese
-
Abstract:
This study investigated the influence of silencing TRAF6 with shRNA on lipopolysac-charide (LPS)/toll-like receptor (TLR)-4 signaling pathway in vitro. Four plasmids (pGCsi-TRAF6-shRNA 1, 2, 3, 4) containing different shRNA sequences were designed and synthesized. The proliferation of RAW264.7 cells after transfected with these plasmids was measured by MTT assay. Inflammatory cellular models were established by LPS stimulation. Levels of TNF-α, IL-1β and TGF-β1 in the supernatants, mRNA expressions of TRAF6, IL-6 and COX-2, protein expression of TRAF6 and translocation of NF-κB were assayed by ELISA, real-time quantitative PCR and Western blotting, respectively. The results showed that the TRAF6 gene knockdown by RNAi hardly inhibited the proliferation of RAW264.7 cells within 72 h. The mRNA and protein expression of TRAF6 was lower in the TRAF6-shRNA1, 2 groups than in the TRAF6-shRNA3, 4 groups. Therefore, pGCsi-TRAF6-shRNA1, 2 were selected for the subsequent experiments. Our results still showed that pGCsi-TRAF6-shRNA 1, 2 could significantly reduce the production of pro-inflammatory cyto-kines and mediators including TNF-α, IL-1β, IL-6 and COX-2, and inhibit NF-κB nuclear transloca-tion. Moreover, pGCsi-TRAF6-shRNA1, 2 could suppress the release of TGF-β1 at the protein level. It was concluded that the recombinant plasmid pTRAF6-shRNA can, to some extent, inhibit inflam-matory response stimulated by LPS at the initial phase. TRAF6 may become the potential therapeutic target of many inflammation-related diseases.
